|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 3/14/14 AIM ImmunoTech Inc. 10-K 12/31/13 96:16M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.46M
2: EX-10.22 Material Contract HTML 29K
3: EX-10.23 Material Contract HTML 29K
4: EX-21 Subsidiaries List HTML 26K
5: EX-23.1 Consent of Experts or Counsel HTML 27K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 33K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 32K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 27K
67: R1 Document and Entity Information HTML 54K
54: R2 Consolidated Balance Sheets HTML 120K
65: R3 Consolidated Balance Sheets (Parenthetical) HTML 47K
69: R4 Consolidated Statements of Comprehensive Loss HTML 81K
88: R5 Consolidated Statements of Changes in HTML 62K
Stockholders' Equity
56: R6 Consolidated Statements of Changes in HTML 28K
Stockholders' Equity (Parenthetical)
64: R7 Consolidated Statements of Cash Flows HTML 118K
49: R8 Business HTML 31K
38: R9 Summary of Significant Accounting Policies HTML 56K
89: R10 Inventories HTML 39K
71: R11 Options and Equity Warrants HTML 212K
70: R12 Marketable Securities - Unrestricted HTML 88K
76: R13 Marketable Securities - Restricted HTML 133K
77: R14 Patents, Trademark Rights and Other Intangibles HTML 33K
74: R15 Accrued Expenses HTML 39K
78: R16 Stockholders' Equity HTML 341K
66: R17 Segment and Related Information HTML 34K
68: R18 Research, Consulting and Supply Agreements HTML 43K
73: R19 401(k) Plan HTML 30K
96: R20 Royalities, License and Employment Agreements HTML 64K
84: R21 Leases HTML 38K
60: R22 Income Taxes (FASB ASC 740 Income Taxes) And HTML 53K
Subsequent Event
72: R23 Contingencies HTML 74K
62: R24 Certain Relationships and Related Transactions HTML 46K
29: R25 Concentrations of Credit Risk HTML 30K
85: R26 Fair Value HTML 131K
92: R27 Margin Account Loan HTML 31K
44: R28 Subsequent Events HTML 33K
43: R29 Quarterly Results of Operation HTML 122K
47: R30 Summary of Significant Accounting Policies HTML 112K
(Policies)
48: R31 Summary of Significant Accounting Policies HTML 39K
(Tables)
50: R32 Inventories (Tables) HTML 35K
23: R33 Options and Equity Warrants (Tables) HTML 195K
82: R34 Marketable Securities - Unrestricted (Tables) HTML 64K
58: R35 Marketable Securities - Restricted (Tables) HTML 107K
61: R36 Accrued Expenses (Tables) HTML 38K
33: R37 Stockholders' Equity (Tables) HTML 472K
95: R38 Leases Leases (Tables) HTML 34K
16: R39 Income Taxes (FASB ASC 740 Income Taxes) And HTML 42K
Subsequent Event (Tables)
51: R40 Fair Value (Tables) HTML 107K
87: R41 Quarterly Results of Operation (Tables) HTML 122K
31: R42 Business Business (Details) HTML 29K
42: R43 Summary of Significant Accounting Policies HTML 46K
(Narrative) (Details)
46: R44 Summary of Significant Accounting Policies HTML 38K
(Schedule of Property, Plant, and Equipment)
(Details)
55: R45 Inventories (Details) HTML 32K
22: R46 Options and Equity Warrants (Narrative) (Details) HTML 47K
37: R47 Options and Equity Warrants (Valuation HTML 47K
Assumptions) (Details)
18: R48 Options and Equity Warrants (Option Activity) HTML 154K
(Details)
86: R49 Marketable Securities - Unrestricted (Narrative) HTML 31K
(Details)
30: R50 Marketable Securities - Unrestricted (Available HTML 44K
for Sale Securities) (Details)
83: R51 Marketable Securities - Unrestricted Marketable HTML 47K
Securities - Unrestricted (Schedule of Unrealized
Losses) (Details)
34: R52 Marketable Securities - Restricted (Narrative) HTML 36K
(Details)
52: R53 Marketable Securities - Restricted (Restricted HTML 48K
Securities) (Details)
17: R54 Marketable Securities - Restricted (Unrealized HTML 42K
losses on investments restricted from sale)
(Details)
21: R55 Patents, Trademark Rights and Other Intangibles HTML 56K
(Details)
45: R56 Accrued Expenses (Details) HTML 44K
25: R57 Stockholders' Equity (Narrative) (Details) HTML 92K
90: R58 Stockholders' Equity (Equity Distribution HTML 57K
Agreement) (Details)
57: R59 Stockholders' Equity (Stock Warrants Weighted HTML 52K
Average Assumptions) (Table) (Details)
75: R60 Stockholders' Equity (Option and Warrant HTML 132K
Rollforwards) (Details)
36: R61 Stockholders' Equity (Rights Offering) (Details) HTML 45K
39: R62 Segment and Related Information Segment and HTML 27K
Related Information (Details)
81: R63 Research, Consulting, and Supply Agreements HTML 59K
(Details)
79: R64 401(k) Plan (Details) HTML 36K
59: R65 Royalties, License and Employment Agreements HTML 98K
(Details)
80: R66 Leases (Details) HTML 28K
35: R67 Leases Leases - Future Minimum Payments Schedule HTML 45K
(Details)
63: R68 Income Taxes (FASB ASC 740 Income Taxes) And HTML 44K
Subsequent Event (Details)
91: R69 Income Taxes (FASB ASC 740 Income Taxes) And HTML 46K
Subsequent Event (Schedule of Deferred Tax Assets)
(Details)
20: R70 Contingencies (Details) HTML 51K
28: R71 Certain Relationships and Related Transactions HTML 66K
(Details)
53: R72 Fair Value (Fair Value Assumptions) (Narrative) HTML 60K
(Details)
24: R73 Fair Value Fair Value - Probability of Put HTML 29K
Liability (Details)
94: R74 Fair Value (Assets and Liabilities Measured on a HTML 64K
Recurring Basis) (Details)
32: R75 Margin Account Loan (Details) HTML 48K
26: R76 Subsequent Events (Details) HTML 43K
27: R77 Quarterly Results of Operations (Unaudited) HTML 61K
(Details)
93: XML IDEA XML File -- Filing Summary XML 142K
19: EXCEL IDEA Workbook of Financial Reports XLSX 330K
41: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 2.66M
10: EX-101.INS XBRL Instance -- heb-20131231 XML 3.71M
12: EX-101.CAL XBRL Calculations -- heb-20131231_cal XML 209K
13: EX-101.DEF XBRL Definitions -- heb-20131231_def XML 760K
14: EX-101.LAB XBRL Labels -- heb-20131231_lab XML 1.77M
15: EX-101.PRE XBRL Presentations -- heb-20131231_pre XML 1.11M
11: EX-101.SCH XBRL Schema -- heb-20131231 XSD 222K
40: ZIP XBRL Zipped Folder -- 0000946644-14-000005-xbrl Zip 294K
| 10.23 Bio Ridge |
/S/: William A. Carter | |
(signature) | |
William
A. Cartrer | |
(print name) | |
CEO and Chairman | |
(Title) | |
7/23/2013 | |
(Date) | |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 8/14/14 | None on these Dates | |||
| Filed on: | 3/14/14 | |||
| For Period end: | 12/31/13 | |||
| 7/19/13 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/19/24 AIM ImmunoTech Inc. S-1 6:628K M2 Compliance LLC/FA 4/01/24 AIM ImmunoTech Inc. 10-K 12/31/23 84:8.7M M2 Compliance LLC/FA 3/31/23 AIM ImmunoTech Inc. 10-K 12/31/22 87:8.7M M2 Compliance LLC/FA 8/15/22 AIM ImmunoTech Inc. 10-Q 6/30/22 72:6M M2 Compliance LLC/FA 5/13/22 AIM ImmunoTech Inc. 10-Q 3/31/22 68:5.6M M2 Compliance LLC/FA 3/31/22 AIM ImmunoTech Inc. 10-K 12/31/21 90:9.3M M2 Compliance LLC/FA 3/31/21 AIM ImmunoTech Inc. 10-K 12/31/20 94:7.6M M2 Compliance LLC/FA |